Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $94.40.
A number of equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $92.00 price objective on shares of LeMaitre Vascular in a research report on Friday, September 20th.
Read Our Latest Analysis on LeMaitre Vascular
Insiders Place Their Bets
Institutional Trading of LeMaitre Vascular
A number of institutional investors and hedge funds have recently modified their holdings of LMAT. YHB Investment Advisors Inc. acquired a new stake in shares of LeMaitre Vascular in the first quarter worth $36,000. GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares during the last quarter. West Oak Capital LLC acquired a new stake in shares of LeMaitre Vascular in the second quarter worth $58,000. USA Financial Formulas acquired a new stake in shares of LeMaitre Vascular in the third quarter worth $60,000. Finally, nVerses Capital LLC lifted its stake in shares of LeMaitre Vascular by 33.3% in the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.
LeMaitre Vascular Price Performance
NASDAQ LMAT opened at $90.39 on Wednesday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $93.24. The company’s 50 day simple moving average is $87.70 and its 200 day simple moving average is $80.17. The company has a market capitalization of $2.03 billion, a P/E ratio of 59.86, a PEG ratio of 2.41 and a beta of 0.88.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter in the previous year, the business earned $0.37 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. On average, analysts anticipate that LeMaitre Vascular will post 1.85 earnings per share for the current year.
LeMaitre Vascular Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.71%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is 42.38%.
About LeMaitre Vascular
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Featured Stories
- Five stocks we like better than LeMaitre Vascular
- Stock Sentiment Analysis: How it Works
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Compound Interest and Why It Matters When Investing
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What is the Nasdaq? Complete Overview with History
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.